Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
The next-generation berberine redefines efficacy standards in the nutraceutical industry
Zeus Hygia Lifesciences, a leading innovator in nutraceutical solutions, has launched Metaberine, a green process-enriched berberine developed using proprietary BioSOLVE Technology. Designed to overcome the limitations of conventional berberine extracts, Metaberine delivers enhanced solubility, superior bioavailability, and a quicker onset of action, all at a significantly lower dose.
The increasing prevalence of sedentary lifestyles and unhealthy dietary habits is contributing to a surge in metabolic disorders, with diabetes now affecting over 800 million adults worldwide. In recent years, GLP-1 receptor agonists have gained popularity due to their dual benefits, which include improving glycemic control and aiding in weight management. However, high costs and limited accessibility of GLP-1 treatments highlight the urgent need for more affordable, effective alternatives. Emerging oral formulations aim to enhance convenience and affordability, and Metaberine, promising faster results at lower doses, can help meet this critical need.
Berberine is a naturally occurring alkaloid found in Berberine roots (Indian Barberry) and other plants. It is well-recognized for supporting metabolic health, cardiovascular function, and healthy lipid and glucose metabolism.
Despite its proven benefits, conventional berberine extracts face significant limitations:
- Poor bioavailability: Less than 2 per cent absorption into the bloodstream
- High dosage requirement: Typically, 500–1500 mg/day in divided doses
- Delayed onset of action
- Gastrointestinal side effects: Including diarrhea, bloating, and nausea
Additionally, its low solubility slows therapeutic impact, making sustained results harder to achieve without long-term, high-dose use.
“Our proprietary BioSOLVE Technology, utilising a 100 per cent aqueous process, produces a highly uniform, porous powder with dramatically improved solubility and bioavailability,” said Dr Arunkanth Krishnakumar, Co-founder and CEO, Zeus Hygia. “This innovation allows Metaberine to deliver results faster, at significantly lower doses—200 mg per day versus the 500–1500 mg typically required with regular extracts—while reducing digestive discomfort.”
Key advantages of Metaberine:
- Enhanced solubility for improved absorption and efficacy
- Lower daily dosage for better compliance
- Reduced side-effect risk due to minimal gastrointestinal impact
- Versatile applications: capsules, sachets, and more
Metaberine is backed by proprietary bioavailability data, with ongoing human clinical trials planned. It is manufactured at Zeus Hygia, adhering to stringent quality and safety certifications.
“With the global rise in metabolic disorders such as diabetes, obesity, and cardiovascular disease, the demand for effective, natural, and safe interventions is higher than ever,” added Dr Krishnakumar. “Metaberine is our solution to that need—a next-generation berberine that redefines efficacy standards in the nutraceutical industry.”